Developed by ImmunoGen, IMGN529 is indicated as a treatment for B-cell malignancies including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
ImmunoGen president and CEO Daniel Junius said they expect IMGN529 to be the first compound in the clinic for NHL that provides Rituxan-like antibody activity along with targeted cell-killing using a potent small molecule.
"The design of IMGN529 takes advantage of the clinical finding that TAP compounds can be dosed at levels at which their antibody component can have anticancer activity," Junius said.